register

News & Trends - Biotechnology

BioCurate moves to next phase of growth with appointment of acting CEO

Health Industry Hub | February 15, 2021 |
[Total: 1    Average: 4/5]

Biotech News: BioCurate, an independently operated joint venture between the University of Melbourne and Monash University, and with support of the Victorian State Government, appoints Dr Damien Bates as Acting CEO, with Founding CEO Dr C. Glenn Begley transitioning to a specialist scientific, commercial and strategic advisory role for the organisation.

An internationally experienced biotech executive, Dr Damien Bates joined BioCurate as Chief Scientific Officer and Head of Translational Medicine nearly two years ago. He has played a critical role in driving the progression of projects along their respective development pathways through close collaborations with the Universities’ researchers and innovation staff, implementation of industry best practice across all aspects of project management, portfolio evaluation, industry engagement and resource allocation, and strong staff support and management.

BioCurate Chairperson the Hon John Brumby AO said the leadership transition marked a critical next step for the company’s development.

We have a well-developed project portfolio, a highly-skilled and committed team, and an excellent relationship with our Shareholder Universities. As Founding CEO, Glenn has made an outstanding contribution to BioCurate and we thank him for his untiring efforts to deliver our vision.

“We welcome Damien, who already knows the business well and has been the driving force behind the progress of our projects. We believe he will bring new energy, breadth of knowledge and focused leadership to all areas of the business,” Mr Brumby said.

As Founding CEO of BioCurate, Dr Begley’s expertise and his deep international experience, together with his passionate commitment to helping drive quality research and translation within the university and medical research sector, has been instrumental to BioCurate’s foundational success. He has led the growth and success of BioCurate through a number of the critical stages including building BioCurate’s investment portfolio of highly prospective projects through the review of > 100 early-stage research projects.

“I am most proud of the staff and team culture that BioCurate has built and remain fully committed to the vision. I am delighted with Damien’s appointment – he, COO Linda Peterson and the BioCurate team, have my unwavering support. I look forward to supporting them as the company moves through its next exciting phase,” Dr Begley said.

Dr Bates said “It is a great privilege to take over the reins from Glenn. I am looking forward to continuing to work closely with the Board, Shareholders and staff to support research that has commercial potential, and driving projects through to fruition – thereby getting one step closer to realising our mission of translating medical research outputs into high quality preclinical candidates for the bio-pharmaceutical industry and eventually new safe & effective therapies for the community.”

You may also like CSL manufacturing of AstraZeneca COVID-19 vaccine reaches final stages


Medical

Medical Pharma Biotech MedTech - Achieving gender equity for female researchers - Professor Julie Campbell, GSK award winner

Achieving gender equity for female researchers – Professor Julie Campbell, GSK award winner

Health Industry Hub | August 6, 2021 |

Medical News: GSK Australia Award for Research Excellence (ARE) is one of the most prestigious and long-standing awards available to […]

More


News & Trends - Medical Technology

MedTech News - Baxter Healthcare launches on-site pop-up COVID vaccination clinic

Baxter launches on-site pop-up COVID vaccination clinic

Health Industry Hub | August 6, 2021 |

MedTech News: Baxter Healthcare has launched an on-site pop-up vaccination clinic at its Western Sydney site this week to support […]

More


News & Trends - Pharmaceuticals

Pharma News - Cancer treatments minimally impacted during COVID-19 lockdowns in Australia, new study

Cancer treatments minimally impacted during COVID-19 lockdowns in Australia, new study

Health Industry Hub | August 6, 2021 |

Pharma News: Australian cancer patients kept up their pharmaceutical treatments during last year’s COVID-19 lockdowns, a big data study from […]

More


News & Trends - Pharmaceuticals

Pharma News - Could PARP inhibitors benefit more ovarian cancer patients?

Could PARP inhibitors benefit more ovarian cancer patients?

Health Industry Hub | August 6, 2021 |

Pharma News: Researchers have made a discovery that could help more Australian women with ovarian cancer gain access to game-changing […]

More